What You Should Know:

– The healthcare industry is poised for a seismic shift, powered by a disruptive technology: blockchain, according to the market.us, the Blockchain Technology in Healthcare Market report.

– This transformative ledger system is projected to propel the global Blockchain Technology in Healthcare Market to a staggering $750B by 2033, a 69.2% annual growth rate compared to its $3.9B valuation in 2023.

Unleashing the Power of Healthcare Blockchain

Imagine a healthcare system where data breaches are a relic of the past, where medical records flow seamlessly between doctors and patients, and where medication supply chains are transparent and secure. This is the future promised by blockchain, a decentralized digital ledger that guarantees data integrity and revolutionizes information exchange.

From Public Blockchains to Biopharma Applications

• Fort Knox for Medical Records: Blockchain’s encrypted blocks ensure data immutability, safeguarding sensitive information from unauthorized access or manipulation. This translates to enhanced security and peace of mind for both patients and healthcare providers.
• Interoperability Unchained: Incompatible systems have long plagued healthcare data sharing. Blockchain provides a standardized platform, breaking down silos and facilitating seamless information exchange between hospitals, labs, and doctors.
• Empowered Patients, Streamlined Processes: Patients regain control over their health data with blockchain. They can decide who accesses their records and benefit from streamlined administrative processes like billing and claims management.
• Supply Chains on Steroids: From tracking pharmaceuticals to verifying medical equipment authenticity, blockchain brings transparency and traceability to healthcare supply chains, combating counterfeiting and ensuring patient safety.
• Smart Contracts for Smarter Care: Automated agreements through smart contracts reduce administrative burdens and accelerate transactions like insurance claims processing, freeing up resources for improved patient care.

Global Giants Embracing Healthcare Blockchain

Europe leads the charge with a 33% market share, fueled by advanced healthcare infrastructure and data protection regulations like GDPR. North America and Asia-Pacific are catching up, with major players like HMS Holdings, Cerner, and Allscripts exploring blockchain’s potential to revolutionize healthcare.

Challenges to Overcome

Regulatory uncertainties, legacy system compatibility issues, and a lack of standardized protocols present hurdles. However, collaborative efforts and innovative solutions are paving the way for widespread adoption.

Future of Healthcare Blockchain

From personalized healthcare apps to secure clinical trial data management, blockchain’s applications extend beyond today’s boundaries. This transformative technology is poised to empower individuals, optimize healthcare operations, and ultimately, deliver better care for everyone.

What You Should Know:

– Artisight, Inc., a pioneer in AI-Driven smart hospital technology, announced today that it has raised $42M in an oversubscribed Series B funding round.

– The Series B funding will allow Artisight to double its headcount, fuel the development of new AI capabilities, and solidify its position as the leading smart hospital platform.

Smart Hospital Platform: Revolutionizing Care Through AI and Collaboration

Developed by clinicians for clinicians, Artisight’s platform seamlessly blends IoT sensors, deep learning, and open integration to streamline patient care. Imagine a hospital equipped with Artisight’s superpowers:

– Virtual nursing: AI co-pilots assist nurses, freeing up their time for direct patient interaction.

– HIPAA-compliant capabilities: Computer vision, voice recognition, vital sign monitoring, indoor positioning, and actionable analytics reports empower informed decisions.

– Reduced documentation and coordination burden: Clinicians can focus on what matters most – their patients.

– Improved patient outcomes and satisfaction: Artisight’s data-driven insights lead to better care and happier patients.

Results Speak Louder Than Words

Artisight’s impact is not just theoretical. Look no further than Northwestern Medicine, a prestigious healthcare system, for proof:

– 52% reduction in nursing overtime: Artisight empowers nurses, maximizing their efficiency.

– 89% reduction in falls: AI co-pilots keep patients safe and prevent accidents.

– 76% reduction in nursing turnover: Happy nurses stay, creating a stable and positive environment.

– Record-high patient and nurse satisfaction: The Artisight difference is evident in every smile.

“This funding is a game-changer,” says Artisight co-founder and CEO, Dr. Andrew Gostine. “We’ll double our headcount, develop new solutions, and support the nearly 200 hospitals implementing Artisight. We’re the only true ambient intelligence platform, transforming care from clinics to operating rooms.”

What You Should Know:

– St. Joseph’s/Candler Hospital and Morrison Healthcare are revolutionizing hospital food service with the first-ever implementation of Amazon’s Just Walk Out technology in a healthcare facility.

– This groundbreaking move offers patients, visitors, and staff unprecedented convenience and 24/7 access to a variety of food and beverage options.

Frictionless Shopping Meets Employee Convenience

The Just Walk Out-enabled SmartBytes market operates seamlessly. Simply swipe your credit card or, for employees, a badge, and browse the selection of pre-packaged meals, snacks, and drinks. The technology automatically tracks your purchases, and you can leave without waiting in line, with your chosen payment method charged accordingly. This employee badge payment option is a first for Just Walk Out technology!

“This technology supports our smart medicine strategy by providing high-tech solutions for everyone,” says Paul P. Hinchey, President and CEO of St. Joseph’s/Candler. “Candler employees, visitors, and patients can now grab a quick meal or snack without waiting in line, allowing them to focus on what matters most.”

Benefits for Everyone

• 24/7 Access: No more relying on vending machines. SmartBytes is always open, offering a convenient and healthy alternative.
• Improved Patient Experience: Visitors waiting on loved ones can grab a nourishing bite without leaving the hospital.
• Enhanced Employee Satisfaction: Quick and easy access to food during busy shifts boosts morale and productivity.
• Frictionless Shopping: Skip the checkout line and enjoy a seamless shopping experience.

A Model for the Future of Healthcare Dining

Tim Pierce, CEO of Morrison Healthcare, sees this partnership as a groundbreaking step forward: “This technology brings a futuristic approach to hospital food access, benefiting both caregivers and guests. Candler serves as an impressive model for how this can be achieved thoughtfully and strategically.”

What You Should Know:

– Rune Labs, a precision neurology company, announced a strategic $12M funding round, bringing its total to over $42 million. The round was led by Nexus NeuroTech Ventures, a new brain disorder fund, with participation from existing investors.

– This strategic partnership marks a significant step forward in Rune Labs’ mission to revolutionize Parkinson’s disease care through personalized data and cutting-edge technology.

Transforming Parkinson’s Care with Data and AI

Rune Labs’ innovative approach revolves around StrivePD, a comprehensive software ecosystem featuring:

– FDA-cleared Apple Watch integration: Tracks tremors and dyskinesia, providing patients with continuous insights into their symptoms.

– Personalized data dashboards: Offer patients and clinicians valuable data visualizations for informed decision-making.

– Actionable insights powered by AI: Rune Labs is at the forefront of using generative AI to deliver personalized recommendations for managing PD.

Building on Success and Embracing AI

Rune Labs’ achievements extend beyond StrivePD. The company’s StriveStudy platform facilitates clinical trials for promising new therapies, while partnerships with leading innovators like BlueRock Therapeutics and Aspen Neuroscience further strengthen its commitment to personalized care. Additionally, Rune Labs is actively exploring generative AI tools to deliver even more personalized insights to patients at scale.

“For too long, we’ve been waiting for a cure that never comes,” says Benjamin Stecher, Chair of Rune Labs’ Patient Advisory Board and a person living with Parkinson’s. “StrivePD has empowered me to understand my disease better and work with my doctor to manage it more effectively. I believe Rune Labs is on the right track to transform how we receive care and ultimately find a cure for Parkinson’s.”

A Brighter Future for Patients with PD

With its data-driven approach, cutting-edge partnerships, and unwavering commitment to patient empowerment, Rune Labs is on a mission to redefine PD care. This latest funding boost fuels their journey to develop AI-powered solutions that unlock personalized treatment plans, optimize clinical trials, and ultimately, bring hope to the millions living with this debilitating disease.

What You Should Know:

– Labcorp, a global leader in innovative laboratory services, and Hawthorne Effect, Inc., a pioneer in technology-driven clinical trial solutions, have announced a groundbreaking partnership to revolutionize clinical trials with a focus on decentralization.

– This collaboration aims to unlock unprecedented levels of patient diversity, reduce site burden, and accelerate study timelines for pharmaceutical, biotech, and medical device sponsors.

Decentralization: The Future of Clinical Trials

Traditional clinical trials often face limitations, including geographical restrictions, inconvenient patient travel, and underrepresentation of diverse populations. The Labcorp-Hawthorne Effect alliance tackles these challenges head-on by embracing decentralization. Hawthorne Effect’s cutting-edge digital platform allows complex study visits and data collection to be conducted seamlessly in patients’ homes or local communities.

This innovative approach offers a multitude of benefits:

– Increased Patient Diversity and Inclusion: Decentralization removes geographic barriers, making it easier for individuals from diverse backgrounds to participate in trials, leading to more representative study results.

– Reduced Site Burden: By shifting some responsibilities from traditional clinical sites to patients’ homes, the pressure on research centers is lessened, improving overall efficiency.

– Accelerated Enrollment and Timelines: The convenience and flexibility of decentralized trials can attract more participants and streamline study processes, leading to faster completion times.

“At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities,” said Jonathan DiVincenzo, Labcorp’s President of Central Laboratories and International. “Through this collaboration, we look forward to combining Labcorp’s global laboratory network and logistics capabilities with Hawthorne Effect’s digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.”

What You Should Know:

– Commons Clinic, a leading value-based physician group transforming musculoskeletal (MSK) care, today announced the launch of the Center for Spine Economics, Outcomes & Research (SEOR).

– This landmark initiative marks a $100M commitment over the next decade to revolutionize ambulatory spine care delivery, paving the way for more effective, affordable, and patient-centered treatment.

Spine Care in Crisis

Millions of Americans suffer from chronic back pain, with many facing unnecessary surgeries and ineffective treatments. The Center for SEOR aims to address this crisis head-on by:

– Championing motion preservation: Prioritizing minimally invasive and ultra-minimally invasive procedures, biologic treatments, and non-surgical interventions to protect patient mobility and long-term health.

– Deconstructing the “surgery trap”: Exposing the prevalence of low-value surgeries, often resulting in “failed back syndrome” and cascading costs.

– Advancing evidence-based practices: Leveraging research and data to develop and implement high-value care models, supported by cutting-edge technology and transparent pricing.

Center for SEOR’s Five-Pillar Approach

The Center for SEOR will operate on five core pillars:

1. Center-of-Excellence for Spinal Restoration: Creating collaborative care teams equipped to deliver optimal results through specialized surgery centers and community clinics.

2. Technology Lab: Fostering innovation in surgical techniques, devices, and applications to improve outcomes and patient experience.

3. Payment Innovation Coalition: Developing new payment models and consumer advocacy policies to incentivize value-based care nationwide.

4. Research Institute: Publishing real-world evidence and open-source data to guide future advancements in spine care.

5. Post-Fellowship Training Program: Equipping the next generation of MSK physicians with the skills and knowledge to lead the future of spine health.

“The Center for SEOR will illuminate a path forward,” stated Dr. Bae, “equipping physicians with the tools and knowledge they need to move away from outdated hospital models and deliver high-value, patient-centered care,” said Drs. Hyun Bae and Sanjay Khurana, Co-Chairs of the CSEOR.

What You Should Know:

– A glimmer of hope shines through for hospitals, according to November data from Kaufman Hall’s National Hospital Flash Report points to ongoing stabilization and even growth.

– While the scars of the pandemic and economic challenges remain, key indicators suggest gradual recovery, with operating margins edging up and revenue streams climbing.

Margins on the Rise, Though Gap Between Performers Persists

The median calendar year-to-date operating margin index for hospitals in November 2023 reached 2.0%, marking a welcome improvement compared to the previous year. Inpatient and outpatient revenue experienced positive growth, rising 5% and 9% respectively. This trend is further bolstered by a decline in total expense per adjusted discharge and a simultaneous increase in revenue per adjusted discharge – both signs of financial progress.

Patient Acuity Normalizes, Value-Based Care Takes Center Stage

The average length of stay in hospitals dropped 6% year-over-year, indicating a return to more typical patient acuity levels. This shift presents significant opportunities for healthcare organizations embracing value-based and bundled payment models, as they can transition patients to the most appropriate care settings while optimizing financial performance.

Embracing Strategic Growth: The Key to Sustainable Success

“Hospitals should leverage this period of relative stability to re-ignite strategic growth initiatives if they aim to thrive in 2024 and beyond,” emphasizes Erik Swanson, senior vice president of Data and Analytics at Kaufman Hall. “Growth strategies will differ based on individual needs and market realities, but all leaders must prioritize goals beyond just profitability and scale. Business model transformation and diversification are equally essential for long-term success.”

Actionable Insights for Hospital Leaders in 2024

Now is the time for hospitals to re-embrace strategic growth to succeed in 2024 and beyond. Kaufman Hall outlines the following 4 key action steps for hospitals:

• Cutbacks won’t cut it: Rethink the “cut our way to viability” approach and shift focus towards strategic growth and reinvestment.
• Growth requires dedication: Achieving meaningful growth demands discipline, perseverance, and adaptability.
• Identify your growth vectors: Explore relevant options like market expansion, essentialization of services, and competitive repositioning.
• Ask the crucial questions: Evaluate your market size, market essentiality, and competitive position to craft an effective growth strategy.

The path to a brighter future for hospitals lies in actively pursuing strategic growth. By leveraging emerging opportunities and focusing on long-term goals beyond just financial metrics, healthcare organizations can pave the way for sustainable success in the evolving healthcare landscape.

What You Should Know:

– The year 2023 saw a stark shift in the digital health funding landscape, according to Rock Health’s annual year-end digital health funding report. Gone were the days of exuberant funding rounds and endless optimism.

– Instead, we witnessed a contraction, with venture capital drying up and startups scrambling to stay afloat. But amidst the turbulence, there were also signs of resilience, innovation, and a necessary course correction.

2023: A Year of Transition and Creative Measures

• Funding Plunges: Annual digital health venture funding reached a four-year low of $10.7B, with fewer deals and smaller amounts.
• M&A Activity Remains Muted: Despite expectations of a surge in acquisitions, the pace remained surprisingly slow.
• No Startup Apocalypse: While shutdowns were anticipated, most companies managed to weather the storm through creative financing tactics like extension rounds, unlabeled raises, and even “silent deals” with existing investors.
• IPO drought: No digital health companies went public in 2023, adding to the uncertainty.

2024: Facing Reality and Embracing Change

• Labeled Rounds Return, But with Adjustments: Startups that bought time in 2023 will need to raise again, likely at lower valuations and with a renewed focus on outcomes and commercial viability.
• M&A Takes Center Stage: Expect to see more mergers and acquisitions, as cash-strapped companies seek exits and larger players consolidate the market.
• Public Market Recalibration: Delistings are likely for struggling companies, while strong performers may finally aim for IPOs, leading to a more stable public health tech sector.
• Tough Choices and New Beginnings: Some startups will close their doors, but their talent and ideas will live on, potentially fueling new ventures or innovations within established companies.
• Emerging Segments Take Flight: Areas like digital obesity care and value-based care enablement, which saw early traction in 2023, could become the next big thing in 2024.

The Road Ahead: A More Efficient and Sustainable Ecosystem

The coming year will be a period of reckoning for the digital health industry. While some may see it as a harsh reality check, it’s also an opportunity for a much-needed reset. By weeding out weaker players and forcing innovation through resourcefulness, 2024 could pave the way for a more efficient, sustainable, and ultimately, more impactful digital health ecosystem.

What You Should Know:

– Mayo Clinic Platformv and Techcyte have joined forces to revolutionize the field of pathology by creating a digital pathology platform. This platform aims to pioneer the next generation of pathology services through an open, AI-driven solution, enhancing treatment, efficiency, and accuracy globally.

– By enabling healthcare organizations to economically digitize their pathology practices, the platform integrates innovative technical and AI workflow solutions.

Transform Global Practice of Pathology

The collaborative effort emphasizes patient-centric innovation and brings together diverse stakeholders, including pathologists, LIS vendors, whole slide scanner manufacturers, AI providers, and more. The platform, an extension of Techcyte’s clinical pathology platform, unifies clinical and anatomic pathology into a comprehensive solution, marking a significant advancement in diagnostic practices.

“Mayo Clinic puts the needs of the patient first. That inspires us to innovate, discovering new cures and testing new care models across the many domains of medicine. Our collaboration with Techcyte will produce a global digital pathology platform, bringing together privacy-protected data sources, solution developers, and caregivers,” says John Halamka, M.D., president of Mayo Clinic Platform.

What You Should Know:

– Arineta Cardio Imaging, a pioneer in cutting-edge cardiovascular imaging solutions, has appointed seasoned medical device leader Doug Ryan as its new CEO.

– Ryan brings 30 years of expertise in building business infrastructure and crafting market strategies for global healthcare giants, poised to propel Arineta to new heights in the fight against cardiovascular disease.

Proven Track Record of Success

Prior to joining Arineta, Ryan held pivotal leadership positions at industry giants like Siemens Healthineers and Samsung Electronics. At Siemens, he spearheaded the expansion of their Computed Tomography business, while at Samsung, he led the Health and Medical Equipment group. His earlier success in launching multi-slice CT in the U.S. for Toshiba American Medical Systems demonstrates his proven ability to translate innovative technology into tangible market impact.

Driving Innovation for Life-Saving Technology

Ryan’s passion for Arineta stems from its dedication to providing the highest quality cardiac and thoracic CT imaging. The company’s flagship SpotLight and SpotLight™ Duo scanners, the world’s only dedicated cardiovascular CT systems, offer unmatched benefits. Their unique combination of temporal resolution, coverage, and cost-effectiveness positions them as groundbreaking solutions in the field.

“Arineta’s vision deeply resonates with me,” says Ryan. “There are still thousands of patients worldwide who lack access to life-saving technology like the SpotLight Cardiac CT. With its speed, quality, and accuracy, Arineta’s solutions have the potential to save lives, and it’s our mission to make them globally accessible.”

What You Should Know:

– Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.

– Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election.

– This strategic move positions Veracyte to significantly expand its offerings across the cancer care continuum, offering a more comprehensive and personalized approach to cancer management.

Taking MRD Detection to the Next Level

Early detection of MRD recurrence can lead to early intervention and improved survival rates for patients. C2i’s technology analyzes entire genomes, generating broader and more accurate MRD signatures compared to traditional methods. This allows for earlier detection of tumor recurrence, leading to potentially better patient outcomes. C2i’s tests require only a small blood sample and deliver results in as little as two weeks, significantly faster than many existing methods. This translates to quicker treatment adjustments and improved patient anxiety management.

Unlocking the Potential of Early Detection

Veracyte plans to leverage C2i’s technology to develop MRD tests for other high-impact cancer indications, further solidifying its position as a leader in precision oncology. This acquisition builds on Veracyte’s existing portfolio of diagnostic and prognostic tests, allowing it to offer a more comprehensive suite of tools for managing cancer throughout the patient journey. By providing accurate and timely information about MRD status, Veracyte empowers clinicians to tailor treatment plans, optimize patient outcomes, and minimize unnecessary interventions. Further integration of C2i Genomics’ technology is planned across multiple cancer indications, paving the way for a future where personalized cancer care becomes the standard, not the exception.

“MRD detection is a critical piece of the puzzle for monitoring treatment success and guiding future decisions,” says Marc Stapley, Veracyte CEO. “C2i Genomics’ technology holds immense potential to revolutionize patient care by enabling earlier detection of recurrence than ever before.”

What You Should Know:

– Buckeye Health Plan and Cityblock are teaming up to provide integrated, community-based care to approximately 10,000 underserved Medicaid recipients in the Cleveland-Akron-Canton area.

– The strategic partnership promises to redefine healthcare delivery for vulnerable communities, prioritizing whole-person health and tackling barriers to access in Ohio.

Building Bridges, Improving Outcomes

Buckeye is a leading Ohio Medicaid managed care plan serving over 428,000 members, offering primary care through its extensive provider network. Cityblock’s model integrates clinical care with social support, addressing factors like food insecurity and housing that impact health outcomes. As part of the partnership, Buckeye will connect Cityblock providers to members who haven’t seen their primary care physician in a year, promoting preventive care and chronic disease management. Cityblock’s 24/7 wrap-around services provide virtual, in-home, and clinic-based care, extending access and convenience.

This partnership holds significant promise for improving healthcare access, equity, and outcomes for thousands of Medicaid recipients in Ohio. By combining Buckeye’s reach with Cityblock’s innovative model, this collaboration paves the way for a more holistic and effective approach to healthcare delivery, prioritizing the needs of underserved communities.

“We’re thrilled to partner with Cityblock to further address the physical, behavioral, environmental and social factors that impact health,” says Dr. Brad Lucas, Buckeye Chief Medical Officer.

What You Should Know:

– Amazon launches its new Health Condition Programs to simplify access to digital health benefits offered by insurance plans and employers.

– By partnering with companies like Omada Health, Amazon brings awareness and enrollment options directly to patients where they’re already looking for health information. This collaboration targets conditions like diabetes prevention, diabetes management, and hypertension, impacting millions of Americans.

How Amazon’s Health Condition Programs Work

– Effortless Discovery: Visit the Amazon Health webpage for a quick coverage check. If eligible, you’ll be guided toward relevant programs like Omada’s offerings for diabetes prevention, management, and hypertension control.

– Seamless Enrollment: No more navigating complex websites or phone calls. Amazon streamlines the enrollment process, making it easier to join Omada’s programs and unlock the potential for improved health outcomes.

– Personalized Support: Omada’s programs provide comprehensive support, including connected devices, health coaching, nutrition planning, and more. This holistic approach empowers individuals to manage their chronic conditions effectively.

More Than Just a Program

Amazon’s initiative tackles the crucial issue of low awareness surrounding digital health benefits, empowering individuals to take charge of their health. This innovative approach paves the way for a future where technology empowers patients, connecting them with the resources they need to manage chronic conditions effectively.

“Amazon wants to make it easier for people to get and stay healthy, and part of that is making it easier to discover the products, services, and professionals that can help them do that. Many people aren’t aware of the health care benefits they’re eligible for, that are typically no cost or subsidized by their employer or insurance plan,” said Aaron Martin, vice president of healthcare at Amazon. “When customers are shopping for health-related products on Amazon, we can surface these additional health care benefits to them to provide even more support in improving their health, at no additional cost.”

What You Should Know:

– Amgen, a global leader in biotechnology, is embarking on a groundbreaking venture: Project Freyja.

– The new initiative will harness the power of an NVIDIA DGX SuperPOD, christened after the Norse goddess of prediction, to accelerate drug discovery and development through AI-powered insights from one of the world’s largest human datasets.

Advance Drug Discovery Using NVIDIA DGX SuperPOD-Powered Insight

• Human Diversity Atlas: Freyja will map the landscape of human genetic variation, creating an invaluable atlas for identifying drug targets and disease-specific biomarkers. This will pave the way for personalized medicine, tailoring treatments to individual patients based on their unique genetic makeup.
• Precision Medicine Revolution: Equipped with Freyja’s AI capabilities, Amgen researchers will develop cutting-edge precision medicine models, potentially enabling the creation of individualized therapies for a multitude of serious diseases.
• Diagnostics Made Easy: By identifying novel biomarkers, Freyja will empower the development of accurate and efficient diagnostics for monitoring disease progression and response to treatment.

Unleashing the Power of Data

• DGX SuperPOD: A powerhouse of computing, the SuperPOD boasts 248 NVIDIA H100 Tensor Core GPUs, allowing Amgen to train state-of-the-art AI models in days, not months. This dramatically accelerates the pace of data analysis and discovery.
• 200 Petabytes of Insights: Freyja will draw upon deCODE genetics’ vast library of deidentified human data, exceeding 200 petabytes, encompassing nearly 3 million individuals. This unparalleled resource provides a unique window into human diversity and its role in health and disease.

“Freyja embodies our commitment to leveraging the convergence of technology and biotechnology. By combining our world-class human data with NVIDIA’s cutting-edge AI technology, we are poised to unlock a new era of drug discovery,” said David M. Reese, Amgen’s Chief Technology Officer.

What You Should Know:

– Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott’s latest FreeStyle Libre 2 Plus sensor.

– The integration brings the benefits of advanced closed-loop technology to millions of Americans living with diabetes, helping them achieve better blood sugar control and manage their condition with greater ease.

Seamless Integration for Precise Control:

The t:slim X2 insulin pump, equipped with Control-IQ technology, now wirelessly connects with the FreeStyle Libre 2 Plus sensor. This continuous glucose monitoring (CGM) system delivers minute-by-minute glucose data directly to the pump and its accompanying app. Control-IQ then utilizes this real-time information to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every five minutes, preventing both hyperglycemia and hypoglycemia.

Key benefits for users

– Reduced burden: The integration simplifies diabetes management by eliminating finger pricks and the need for separate CGM devices.

– Improved blood sugar control: Control-IQ’s proactive insulin adjustments help prevent high and low blood sugar levels, leading to better overall glucose management.

– Personalized experience: The system is highly customizable, allowing users to adjust settings to suit their individual needs and preferences.

Abbott’s Innovation

The FreeStyle Libre 2 Plus sensor boasts several features that make it ideal for AID compatibility:

– 15-day wear time: This extended wear period reduces the need for frequent sensor changes, offering convenience and cost savings.

– Proven accuracy: The sensor delivers highly accurate glucose readings, ensuring reliable data for Control-IQ’s algorithms.

– Discreet and comfortable: The sensor is small and lightweight, making it comfortable to wear for extended periods.

“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”